Viral Genetics, Inc. (OTC BB: VRAL) previously stated its expectation that the results of the Phase III human clinical trial conducted in South Africa would be available by today. While this expectation will not be met today, Viral Genetics expects no significant delay in the release of the results of the clinical trial conducted in South Africa.
